Home / Therapies / SGLT-2 Therapy Center (page 20)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Full Interview: Dr. Bruce Neal, CANVAS and CANVAS-R

Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. Featured videos include: Pt.1: CANVAS Program …

Read More »

Current Video Interview: Dr. Matthew Weir

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have a special interview with one of the presenters at the AACE 26th Annual Scientific & Clinical Congress in Austin, Texas. Dr. Weir discusses the pros and cons of SGLT-2 inhibitors in clinical practice.

Read More »

Did You Know: Safety Concerns for Diabetes Medications

When it comes to antidiabetic therapies, professionals should be aware of safety concerns with concentrated insulin formulations, metformin and renal function, and SGLT-2 inhibitors and DKA. See the breakdown of these safety issues by Tom Palma, RPh, MS, BCPS, and Greg Wiggers, PharmD, PhD, plus exclusive commentary by DIC Advisory Board member Dr. George Bakris.

Read More »